查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830718

2025年全球癌症體外診斷（IVD）市場報告

Cancer In Vitro Diagnostics (IVD) Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，癌症體外診斷 (IVD) 市場規模強勁成長，從 2024 年的 133.6 億美元增加到 2025 年的 143.2 億美元，複合年成長率為 7.2%。預測期內的成長歸因於癌症生物標記研究的興起、需要診斷測試的癌症臨床試驗的增加、政府醫療保健計劃的擴展、檢測基礎設施的完善以及生物技術研究資金的增加。

預計未來幾年癌症體外診斷 (IVD) 市場規模將強勁成長，到 2029 年將達到 186.2 億美元，複合年成長率為 6.8%。預測期內的成長可歸因於政府和非政府組織主導的癌症篩檢計畫、人口老化、人們對早期癌症檢測的認知不斷提高、保險報銷範圍的擴大以及照護現場(POC) 的普及。這段時期的主要趨勢包括液態切片技術的擴展、次世代定序的進步、人工智慧和機器學習的融合、微流體的引入以及數位病理解決方案的採用。

體外癌症診斷 (IVD) 是在人類體外對血液、組織或其他體液等樣本進行的診斷測試，用於檢測、監測和管理癌症。這些測試透過分析生物標記、基因突變和其他癌症相關指標，有助於早期發現、診斷、預後和治療選擇。

該公司在癌症體外診斷 (IVD) 領域的主要產品類型包括試劑和套件、儀器、軟體和服務。試劑和套件是即用型化學品和預處理測試材料，用於檢測癌症標記和體外診斷 (IVD) 測試中的樣本分析。它們採用臨床化學、免疫化學、免疫檢測、血液學、凝血和止血、微生物學和分子診斷等技術。這些診斷涵蓋多種癌症類型，包括乳癌、肺癌、前列腺癌和大腸癌，並服務於醫院、實驗室、學術機構、就地檢驗中心和患者自我檢測項目等終端用戶。

2025年春季美國關稅的突然上調及其引發的貿易摩擦嚴重影響了醫療保健產業，尤其是關鍵醫療設備、診斷設備和藥品的供應。醫院和醫療機構面臨進口手術器械、影像設備以及注射器和導管等消耗品成本上漲的問題。這些成本上漲給醫療保健預算帶來了巨大壓力，導致一些醫療機構推遲設備升級或將成本轉嫁給患者。此外，原料和零件的關稅阻礙了基本藥品和醫療設備的生產，造成了供應鏈瓶頸。為此，該行業正在籌資策略多元化，盡可能促進本地生產，並倡導對緊急醫療產品免關稅。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供癌症體外診斷 (IVD) 市場統計數據，例如全球市場規模、區域佔有率、競爭對手的市場佔有率、癌症體外診斷 (IVD) 細分市場、市場趨勢和機遇，以及您在癌症體外診斷 (IVD) 行業取得成功所需的數據。本癌症體外診斷 (IVD) 市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切觀點。

癌症發病率的上升預計將推動癌症體外診斷 (IVD) 市場的未來成長。癌症是指體內異常細胞不受控制地增生和擴散，侵入鄰近組織並形成腫瘤。由於預期壽命的增加和感染疾病死亡率的降低，越來越多的老年人面臨罹癌的高風險。透過對患者樣本進行臨床測試，癌症體外診斷 (IVD) 可支持疾病的早期發現、監測和管理，從而能夠及時做出治療決策並改善結果。例如，2024 年 2 月，總部位於瑞士的政府間組織世界衛生組織 (WHO) 報告稱，預計 2022 年全球新增癌症病例將達到 2,000 萬，到 2050 年將增至 3,500 萬，增幅為 77%。因此，癌症發生率的上升正在推動癌症體外診斷 (IVD) 市場的成長。

癌症體外診斷 (IVD) 市場的主要企業正專注於技術進步，例如 CE 標誌的體外診斷 (IVD) 癌症檢測套組，以提高臨床環境中遺傳性癌症檢測的可及性、準確性和標準化。 CE 標誌的 IVD 癌症檢測套組是符合歐盟體外診斷藥物指令 (IVDD) 的診斷檢測，確保實驗室使用的性能、安全性和品質檢驗。例如，2022 年 2 月，美國基因醫學公司 Invitae 在歐洲推出了 FusionPlex Dx 和 LiquidPlex Dx。 FusionPlex Dx 可對 FFPE 樣本中的低頻變異進行高靈敏度檢測，而 LiquidPlex Dx 可從血液中進行非侵入性癌症基因組分析，從而在組織樣本有限的情況下促進個人化治療和疾病監測。

2022年2月，美國醫療科技公司BD（Becton, Dickinson & Company）從西班牙生物技術公司Vitro SA手中收購了Cytognos。 Vitro SA是一家專注於癌症IVD（體外診斷）的生技公司。透過此次收購，BD將把其產品組合從癌症檢測和診斷擴展到治療後監測，從而支持全方位的患者照護。

癌症體外診斷 (IVD) 市場由提供癌症篩檢、早期檢測、診斷分析和個人化治療指導等服務的營業單位所獲得的收益所構成。市場價值還包括服務提供者銷售的或包含在其服務產品中的任何相關產品的價值。癌症體外診斷 (IVD) 市場還包括試劑、檢測試劑套件、診斷儀器、分子診斷平台和免疫檢測系統的銷售。該市場的價值為“出廠價”，即產品製造商或創造者向其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接向最終客戶銷售的產品價值。該市場中的產品價值還包括產品創造者銷售的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球體外腫瘤診斷 (IVD)：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球體外癌症診斷（IVD）市場：成長率分析
  • 全球體外癌症診斷 (IVD) 市場表現：規模與成長，2019-2024 年
  • 全球體外癌症診斷 (IVD) 市場預測：2024-2029 年及 2034 年規模與成長
  • 全球癌症體外診斷（IVD）：總目標市場（TAM）

第6章 市場細分

  • 全球癌症體外診斷 (IVD) 市場（依產品類型、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 試劑和套件
  • 裝置
  • 軟體和服務
  • 全球癌症體外診斷 (IVD) 市場技術、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 臨床化學
  • 免疫化學或免疫檢測
  • 血液學
  • 凝血和止血
  • 微生物學
  • 分子診斷
  • 其他技術
  • 全球癌症體外診斷 (IVD) 市場（按癌症類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • 乳癌
  • 肺癌
  • 攝護腺癌
  • 大腸直腸癌
  • 全球體外癌症診斷 (IVD) 市場（按最終用戶、績效和預測），2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 研究所
  • 學術的
  • 就地檢驗
  • 患者自我檢查
  • 其他最終用戶
  • 全球體外癌症診斷 (IVD) 市場：按試劑和套件（按類型）細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • PCR試劑和套件
  • NGS試劑和套件
  • 免疫檢測試劑和套件
  • 原位雜合技術 (ISH) 試劑和套件
  • 其他
  • 全球體外癌症診斷 (IVD) 市場：按設備類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • PCR設備
  • NGS設備
  • 免疫檢測分析儀
  • ISH儀器
  • 其他
  • 全球癌症體外診斷 (IVD) 市場：按軟體和服務細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 數據分析軟體
  • 實驗室資訊管理系統
  • 雲端基礎的資料管理
  • 裝置整合軟體
  • 支援和維護服務

第7章 區域和國家分析

  • 全球癌症體外診斷 (IVD) 市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球癌症體外診斷 (IVD) 市場：按國家、表現和預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 癌症體外診斷（IVD）市場：競爭格局
  • 癌症體外診斷（IVD）市場：公司簡介
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • GE HealthCare Technologies Inc.
  • Hologic Inc.
  • Illumina Inc.
  • bioMerieux SA
  • Sysmex Corporation
  • Exact Sciences Corporation
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Autobio Diagnostics Co Ltd.
  • Transasia Bio-Medicals Ltd.
  • NanoString Technologies Inc.
  • Genetron Holdings Limited
  • Cancer Diagnostics Inc.
  • J. Mitra & Co. Pvt Ltd.
  • Tulip Diagnostics（P）Ltd.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年癌症體外診斷（IVD）市場：提供新機會的國家
  • 2029年癌症體外診斷（IVD）市場：細分領域帶來新機會
  • 2029年癌症體外診斷（IVD）市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r37705

Cancer in vitro diagnostics (IVD) refers to diagnostic tests conducted outside the human body on samples like blood, tissue, or other bodily fluids to detect, monitor, or manage cancer. These tests aid in early detection, diagnosis, prognosis, and treatment selection by analyzing biomarkers, genetic mutations, and other cancer-related indicators.

The primary product types of cancer in vitro diagnostics (IVD) include reagents and kits, instruments, and software and services. Reagents and kits are ready-to-use chemicals and prepared testing materials designed to detect cancer markers and analyze samples in IVD tests. They employ technologies such as clinical chemistry, immunochemistry or immunoassays, hematology, coagulation and hemostasis, microbiology, molecular diagnostics, and others. These diagnostics cover various cancer types, including breast, lung, prostate, and colorectal cancers, and serve end users such as hospitals, laboratories, academic institutions, point-of-care testing centers, and patient self-testing programs.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The cancer in vitro diagnostics (IVD) market research report is one of a series of new reports from The Business Research Company that provides cancer in vitro diagnostics (IVD) market statistics, including cancer in vitro diagnostics (IVD) industry global market size, regional shares, competitors with a cancer in vitro diagnostics (IVD) market share, cancer in vitro diagnostics (IVD) market segments, market trends and opportunities, and any further data you may need to thrive in the cancer in vitro diagnostics (IVD) industry. This cancer in vitro diagnostics (IVD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer in vitro diagnostics (IVD) market size has grown strongly in recent years. It will grow from $13.36 billion in 2024 to $14.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising research in cancer biomarkers, increasing number of oncology clinical trials requiring diagnostic testing, expanding government health initiatives, growth in laboratory infrastructure, and increasing funding for biotechnology research.

The cancer in vitro diagnostics (IVD) market size is expected to see strong growth in the next few years. It will grow to $18.62 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to government and NGO-led cancer screening initiatives, an aging population, increasing awareness of early cancer detection, expanded reimbursement coverage, and growing adoption of point-of-care (POC) diagnostics. Major trends during this period include the expansion of liquid biopsy technologies, advancements in next-generation sequencing, integration of artificial intelligence and machine learning, incorporation of microfluidics, and adoption of digital pathology solutions.

The increasing incidence of cancer is expected to propel the growth of the cancer in vitro diagnostics (IVD) market going forward. Cancer refers to the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and form tumors. The rising incidence of cancer is largely driven by the aging population, as longer life expectancy and reduced mortality from infectious diseases result in more elderly individuals, who are at higher risk of developing cancer. Cancer in vitro diagnostics (IVD) support early detection, monitoring, and management of the disease through laboratory tests on patient samples, enabling timely treatment decisions and improved outcomes. For instance, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that new cancer cases globally reached 20 million in 2022 and are projected to rise to 35 million by 2050, representing a 77% increase. Therefore, the rising incidence of cancer is driving the growth of the cancer in vitro diagnostics (IVD) market.

Key companies in the cancer in vitro diagnostics (IVD) market are focusing on technological advancements, such as CE-marked IVD cancer testing kits, to improve accessibility, accuracy, and standardization of hereditary cancer testing across clinical settings. CE-marked IVD cancer testing kits are diagnostic assays compliant with the European Union's in vitro diagnostic directive (IVDD), ensuring validated performance, safety, and quality for laboratory use. For instance, in February 2022, Invitae, a US-based medical genetics company, launched FusionPlex Dx and LiquidPlex Dx in Europe. FusionPlex Dx provides sensitive detection of low-frequency variants in FFPE samples, while LiquidPlex Dx enables non-invasive cancer genomic profiling from blood, facilitating personalized treatment and disease monitoring when tissue samples are limited.

In February 2022, BD (Becton, Dickinson and Company), a US-based medical technology firm, acquired Cytognos from Vitro S.A., a Spain-based biotechnology company specializing in cancer IVD. This acquisition allows BD to expand its portfolio from cancer discovery and diagnosis into post-treatment monitoring, supporting the full spectrum of patient care.

Major players in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., and Tulip Diagnostics (P) Ltd.

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer in vitro diagnostics (IVD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer in vitro diagnostics (IVD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer in vitro diagnostics (IVD) market consists of revenues earned by entities by providing services such as cancer screening, early detection testing, diagnostic analysis, and personalized treatment guidance. The market value includes the value of related goods sold by the service provider or contained within the service offering. The cancer in vitro diagnostics (IVD) market also includes sales of reagents, assay kits, diagnostic instruments, molecular diagnostic platforms, and immunoassay systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer In Vitro Diagnostics (IVD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer in vitro diagnostics (ivd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer in vitro diagnostics (ivd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer in vitro diagnostics (ivd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Reagents And Kits; Instruments; Software And Services
  • 2) By Technology: Clinical Chemistry; Immunochemistry Or Immunoassays; Hematology; Coagulation And Hemostasis; Microbiology; Molecular Diagnostics; Other Technology
  • 3) By Cancer Type: Breast Cancer; Lung Cancer; Prostate Cancer; Colorectal Cancer
  • 4) By End-Users: Hospitals; Laboratories; Academics; Point-Of-Care Testing; Patient Self-Testing; Other End Users
  • Subsegments:
  • 1) By Reagents And Kits: PCR Reagents And Kits; NGS Reagents And Kits; Immunoassay Reagents And Kits; In Situ Hybridization (ISH) Reagents And Kits; Others
  • 2) By Instruments: PCR Instruments; NGS Instruments; Immunoassay Analyzers; ISH Instruments; Others
  • 3) By Software And Services: Data Analysis Software; Laboratory Information Management Systems; Cloud-Based Data Management; Instrument Integration Software; Support And Maintenance Services
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Siemens Healthineers AG; GE HealthCare Technologies Inc.; Hologic Inc.; Illumina Inc.; bioMerieux SA; Sysmex Corporation; Exact Sciences Corporation; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Autobio Diagnostics Co Ltd.; Transasia Bio-Medicals Ltd.; NanoString Technologies Inc.; Genetron Holdings Limited; Cancer Diagnostics Inc.; J. Mitra & Co. Pvt Ltd.; Tulip Diagnostics (P) Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer In Vitro Diagnostics (IVD) Market Characteristics

3. Cancer In Vitro Diagnostics (IVD) Market Trends And Strategies

4. Cancer In Vitro Diagnostics (IVD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cancer In Vitro Diagnostics (IVD) Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cancer In Vitro Diagnostics (IVD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cancer In Vitro Diagnostics (IVD) Market Growth Rate Analysis
  • 5.4. Global Cancer In Vitro Diagnostics (IVD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cancer In Vitro Diagnostics (IVD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cancer In Vitro Diagnostics (IVD) Total Addressable Market (TAM)

6. Cancer In Vitro Diagnostics (IVD) Market Segmentation

  • 6.1. Global Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents And Kits
  • Instruments
  • Software And Services
  • 6.2. Global Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinical Chemistry
  • Immunochemistry Or Immunoassays
  • Hematology
  • Coagulation And Hemostasis
  • Microbiology
  • Molecular Diagnostics
  • Other Technology
  • 6.3. Global Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • 6.4. Global Cancer In Vitro Diagnostics (IVD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Laboratories
  • Academics
  • Point-Of-Care Testing
  • Patient Self-Testing
  • Other End Users
  • 6.5. Global Cancer In Vitro Diagnostics (IVD) Market, Sub-Segmentation Of Reagents And Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR Reagents And Kits
  • NGS Reagents And Kits
  • Immunoassay Reagents And Kits
  • In Situ Hybridization (ISH) Reagents And Kits
  • Others
  • 6.6. Global Cancer In Vitro Diagnostics (IVD) Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR Instruments
  • NGS Instruments
  • Immunoassay Analyzers
  • ISH Instruments
  • Others
  • 6.7. Global Cancer In Vitro Diagnostics (IVD) Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Analysis Software
  • Laboratory Information Management Systems
  • Cloud-Based Data Management
  • Instrument Integration Software
  • Support And Maintenance Services

7. Cancer In Vitro Diagnostics (IVD) Market Regional And Country Analysis

  • 7.1. Global Cancer In Vitro Diagnostics (IVD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cancer In Vitro Diagnostics (IVD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market

  • 8.1. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer In Vitro Diagnostics (IVD) Market

  • 9.1. China Cancer In Vitro Diagnostics (IVD) Market Overview
  • 9.2. China Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer In Vitro Diagnostics (IVD) Market

  • 10.1. India Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer In Vitro Diagnostics (IVD) Market

  • 11.1. Japan Cancer In Vitro Diagnostics (IVD) Market Overview
  • 11.2. Japan Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer In Vitro Diagnostics (IVD) Market

  • 12.1. Australia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer In Vitro Diagnostics (IVD) Market

  • 13.1. Indonesia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer In Vitro Diagnostics (IVD) Market

  • 14.1. South Korea Cancer In Vitro Diagnostics (IVD) Market Overview
  • 14.2. South Korea Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer In Vitro Diagnostics (IVD) Market

  • 15.1. Western Europe Cancer In Vitro Diagnostics (IVD) Market Overview
  • 15.2. Western Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer In Vitro Diagnostics (IVD) Market

  • 16.1. UK Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer In Vitro Diagnostics (IVD) Market

  • 17.1. Germany Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer In Vitro Diagnostics (IVD) Market

  • 18.1. France Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer In Vitro Diagnostics (IVD) Market

  • 19.1. Italy Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer In Vitro Diagnostics (IVD) Market

  • 20.1. Spain Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market

  • 21.1. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market Overview
  • 21.2. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer In Vitro Diagnostics (IVD) Market

  • 22.1. Russia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer In Vitro Diagnostics (IVD) Market

  • 23.1. North America Cancer In Vitro Diagnostics (IVD) Market Overview
  • 23.2. North America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer In Vitro Diagnostics (IVD) Market

  • 24.1. USA Cancer In Vitro Diagnostics (IVD) Market Overview
  • 24.2. USA Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer In Vitro Diagnostics (IVD) Market

  • 25.1. Canada Cancer In Vitro Diagnostics (IVD) Market Overview
  • 25.2. Canada Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer In Vitro Diagnostics (IVD) Market

  • 26.1. South America Cancer In Vitro Diagnostics (IVD) Market Overview
  • 26.2. South America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer In Vitro Diagnostics (IVD) Market

  • 27.1. Brazil Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer In Vitro Diagnostics (IVD) Market

  • 28.1. Middle East Cancer In Vitro Diagnostics (IVD) Market Overview
  • 28.2. Middle East Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer In Vitro Diagnostics (IVD) Market

  • 29.1. Africa Cancer In Vitro Diagnostics (IVD) Market Overview
  • 29.2. Africa Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer In Vitro Diagnostics (IVD) Market Competitive Landscape And Company Profiles

  • 30.1. Cancer In Vitro Diagnostics (IVD) Market Competitive Landscape
  • 30.2. Cancer In Vitro Diagnostics (IVD) Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Cancer In Vitro Diagnostics (IVD) Market Other Major And Innovative Companies

  • 31.1. GE HealthCare Technologies Inc.
  • 31.2. Hologic Inc.
  • 31.3. Illumina Inc.
  • 31.4. bioMerieux SA
  • 31.5. Sysmex Corporation
  • 31.6. Exact Sciences Corporation
  • 31.7. Bio-Rad Laboratories Inc.
  • 31.8. QIAGEN N.V.
  • 31.9. Autobio Diagnostics Co Ltd.
  • 31.10. Transasia Bio-Medicals Ltd.
  • 31.11. NanoString Technologies Inc.
  • 31.12. Genetron Holdings Limited
  • 31.13. Cancer Diagnostics Inc.
  • 31.14. J. Mitra & Co. Pvt Ltd.
  • 31.15. Tulip Diagnostics (P) Ltd.

32. Global Cancer In Vitro Diagnostics (IVD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer In Vitro Diagnostics (IVD) Market

34. Recent Developments In The Cancer In Vitro Diagnostics (IVD) Market

35. Cancer In Vitro Diagnostics (IVD) Market High Potential Countries, Segments and Strategies

  • 35.1 Cancer In Vitro Diagnostics (IVD) Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cancer In Vitro Diagnostics (IVD) Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cancer In Vitro Diagnostics (IVD) Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer